GlassScriptPhysician profile
Timothy Kaminski
NPI 1912324252
$1,647.72
in general payments reported to CMS, 2019-2025
13 companies · $551 in 2025
The $551 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $29.55 · 2022: $160 · 2023: $382 · 2024: $525 · 2025: $551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,458.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,458.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $614.52 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Abbvie INC. | $318.56 | 2023-2025 | |
| Indivior INC. | $161.52 | 2024-2025 | Sublocade |
| Alkermes, INC. | $125.82 | 2022-2025 | Aristada, Vivitrol, Vivitrol |
| Janssen Pharmaceuticals, INC | $98.43 | 2022-2025 | Spravato, Invega Sustenna |
| E.R. Squibb & Sons, L.L.C. | $81.73 | 2024-2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $52.29 | 2025 | Fanapt |
| Teva Pharmaceuticals USA, INC. | $49.36 | 2021-2024 | Uzedy |
| Axsome Therapeutics, INC. | $42.33 | 2023-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $38.29 | 2025 | Caplyta |
| Neurocrine Biosciences, INC. | $25.61 | 2025 | |
| Braeburn INC. | $22.70 | 2024 | Brixadi |
| Avanir Pharmaceuticals, INC. | $16.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Kaminski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.